1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Radioactive Diagnostic Drugs by Type
  • 1.3.1 Overview: Global Radioactive Diagnostic Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Global Radioactive Diagnostic Drugs Consumption Value Market Share by Type in 2025
  • 1.3.3 Single Photon Drugs
  • 1.3.4 Positron Drugs
  • 1.3.5 Blood Perfusion Drugs
  • 1.3.6 Metabolizing Drugs
  • 1.3.7 Receptor Binding Drugs
  • 1.3.8 Others
• 1.4 Global Radioactive Diagnostic Drugs Market by Application
  • 1.4.1 Overview: Global Radioactive Diagnostic Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 Oncology
  • 1.4.3 Cardiology
  • 1.4.4 Neuroscience
  • 1.4.5 Thyroid
  • 1.4.6 Others
• 1.5 Global Radioactive Diagnostic Drugs Market Size & Forecast
• 1.6 Global Radioactive Diagnostic Drugs Market Size and Forecast by Region
  • 1.6.1 Global Radioactive Diagnostic Drugs Market Size by Region: 2021 VS 2025 VS 2032
  • 1.6.2 Global Radioactive Diagnostic Drugs Market Size by Region, (2021-2032)
  • 1.6.3 North America Radioactive Diagnostic Drugs Market Size and Prospect (2021-2032)
  • 1.6.4 Europe Radioactive Diagnostic Drugs Market Size and Prospect (2021-2032)
  • 1.6.5 Asia-Pacific Radioactive Diagnostic Drugs Market Size and Prospect (2021-2032)
  • 1.6.6 South America Radioactive Diagnostic Drugs Market Size and Prospect (2021-2032)
  • 1.6.7 Middle East & Africa Radioactive Diagnostic Drugs Market Size and Prospect (2021-2032)

2 Company Profiles

• 2.1 Curium
  • 2.1.1 Curium Details
  • 2.1.2 Curium Major Business
  • 2.1.3 Curium Radioactive Diagnostic Drugs Product and Solutions
  • 2.1.4 Curium Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Curium Recent Developments and Future Plans
• 2.2 Medi-Radiopharma
  • 2.2.1 Medi-Radiopharma Details
  • 2.2.2 Medi-Radiopharma Major Business
  • 2.2.3 Medi-Radiopharma Radioactive Diagnostic Drugs Product and Solutions
  • 2.2.4 Medi-Radiopharma Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Medi-Radiopharma Recent Developments and Future Plans
• 2.3 Jubilant Radiopharma
  • 2.3.1 Jubilant Radiopharma Details
  • 2.3.2 Jubilant Radiopharma Major Business
  • 2.3.3 Jubilant Radiopharma Radioactive Diagnostic Drugs Product and Solutions
  • 2.3.4 Jubilant Radiopharma Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Jubilant Radiopharma Recent Developments and Future Plans
• 2.4 Telix
  • 2.4.1 Telix Details
  • 2.4.2 Telix Major Business
  • 2.4.3 Telix Radioactive Diagnostic Drugs Product and Solutions
  • 2.4.4 Telix Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.4.5 Telix Recent Developments and Future Plans
• 2.5 Mallinckrodt
  • 2.5.1 Mallinckrodt Details
  • 2.5.2 Mallinckrodt Major Business
  • 2.5.3 Mallinckrodt Radioactive Diagnostic Drugs Product and Solutions
  • 2.5.4 Mallinckrodt Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.5.5 Mallinckrodt Recent Developments and Future Plans
• 2.6 Cardinal Health
  • 2.6.1 Cardinal Health Details
  • 2.6.2 Cardinal Health Major Business
  • 2.6.3 Cardinal Health Radioactive Diagnostic Drugs Product and Solutions
  • 2.6.4 Cardinal Health Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.6.5 Cardinal Health Recent Developments and Future Plans
• 2.7 Bayer AG
  • 2.7.1 Bayer AG Details
  • 2.7.2 Bayer AG Major Business
  • 2.7.3 Bayer AG Radioactive Diagnostic Drugs Product and Solutions
  • 2.7.4 Bayer AG Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.7.5 Bayer AG Recent Developments and Future Plans
• 2.8 GE Healthcare
  • 2.8.1 GE Healthcare Details
  • 2.8.2 GE Healthcare Major Business
  • 2.8.3 GE Healthcare Radioactive Diagnostic Drugs Product and Solutions
  • 2.8.4 GE Healthcare Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.8.5 GE Healthcare Recent Developments and Future Plans
• 2.9 Mallinckrodt Pharmaceuticals
  • 2.9.1 Mallinckrodt Pharmaceuticals Details
  • 2.9.2 Mallinckrodt Pharmaceuticals Major Business
  • 2.9.3 Mallinckrodt Pharmaceuticals Radioactive Diagnostic Drugs Product and Solutions
  • 2.9.4 Mallinckrodt Pharmaceuticals Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.9.5 Mallinckrodt Pharmaceuticals Recent Developments and Future Plans
• 2.10 Bracco Group
  • 2.10.1 Bracco Group Details
  • 2.10.2 Bracco Group Major Business
  • 2.10.3 Bracco Group Radioactive Diagnostic Drugs Product and Solutions
  • 2.10.4 Bracco Group Radioactive Diagnostic Drugs Revenue, Gross Margin and Market Share (2021-2026)
  • 2.10.5 Bracco Group Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Radioactive Diagnostic Drugs Revenue and Share by Players (2021-2026)
• 3.2 Market Share Analysis (2025)
  • 3.2.1 Market Share of Radioactive Diagnostic Drugs by Company Revenue
  • 3.2.2 Top 3 Radioactive Diagnostic Drugs Players Market Share in 2025
  • 3.2.3 Top 6 Radioactive Diagnostic Drugs Players Market Share in 2025
• 3.3 Radioactive Diagnostic Drugs Market: Overall Company Footprint Analysis
  • 3.3.1 Radioactive Diagnostic Drugs Market: Region Footprint
  • 3.3.2 Radioactive Diagnostic Drugs Market: Company Product Type Footprint
  • 3.3.3 Radioactive Diagnostic Drugs Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Radioactive Diagnostic Drugs Consumption Value and Market Share by Type (2021-2026)
• 4.2 Global Radioactive Diagnostic Drugs Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

• 5.1 Global Radioactive Diagnostic Drugs Consumption Value Market Share by Application (2021-2026)
• 5.2 Global Radioactive Diagnostic Drugs Market Forecast by Application (2027-2032)

6 North America

• 6.1 North America Radioactive Diagnostic Drugs Consumption Value by Type (2021-2032)
• 6.2 North America Radioactive Diagnostic Drugs Market Size by Application (2021-2032)
• 6.3 North America Radioactive Diagnostic Drugs Market Size by Country
  • 6.3.1 North America Radioactive Diagnostic Drugs Consumption Value by Country (2021-2032)
  • 6.3.2 United States Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 6.3.3 Canada Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 6.3.4 Mexico Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)

7 Europe

• 7.1 Europe Radioactive Diagnostic Drugs Consumption Value by Type (2021-2032)
• 7.2 Europe Radioactive Diagnostic Drugs Consumption Value by Application (2021-2032)
• 7.3 Europe Radioactive Diagnostic Drugs Market Size by Country
  • 7.3.1 Europe Radioactive Diagnostic Drugs Consumption Value by Country (2021-2032)
  • 7.3.2 Germany Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 7.3.3 France Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 7.3.4 United Kingdom Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 7.3.5 Russia Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 7.3.6 Italy Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)

8 Asia-Pacific

• 8.1 Asia-Pacific Radioactive Diagnostic Drugs Consumption Value by Type (2021-2032)
• 8.2 Asia-Pacific Radioactive Diagnostic Drugs Consumption Value by Application (2021-2032)
• 8.3 Asia-Pacific Radioactive Diagnostic Drugs Market Size by Region
  • 8.3.1 Asia-Pacific Radioactive Diagnostic Drugs Consumption Value by Region (2021-2032)
  • 8.3.2 China Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 8.3.3 Japan Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 8.3.4 South Korea Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 8.3.5 India Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 8.3.6 Southeast Asia Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 8.3.7 Australia Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)

9 South America

• 9.1 South America Radioactive Diagnostic Drugs Consumption Value by Type (2021-2032)
• 9.2 South America Radioactive Diagnostic Drugs Consumption Value by Application (2021-2032)
• 9.3 South America Radioactive Diagnostic Drugs Market Size by Country
  • 9.3.1 South America Radioactive Diagnostic Drugs Consumption Value by Country (2021-2032)
  • 9.3.2 Brazil Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 9.3.3 Argentina Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)

10 Middle East & Africa

• 10.1 Middle East & Africa Radioactive Diagnostic Drugs Consumption Value by Type (2021-2032)
• 10.2 Middle East & Africa Radioactive Diagnostic Drugs Consumption Value by Application (2021-2032)
• 10.3 Middle East & Africa Radioactive Diagnostic Drugs Market Size by Country
  • 10.3.1 Middle East & Africa Radioactive Diagnostic Drugs Consumption Value by Country (2021-2032)
  • 10.3.2 Turkey Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 10.3.3 Saudi Arabia Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)
  • 10.3.4 UAE Radioactive Diagnostic Drugs Market Size and Forecast (2021-2032)

11 Market Dynamics

• 11.1 Radioactive Diagnostic Drugs Market Drivers
• 11.2 Radioactive Diagnostic Drugs Market Restraints
• 11.3 Radioactive Diagnostic Drugs Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 Radioactive Diagnostic Drugs Industry Chain
• 12.2 Radioactive Diagnostic Drugs Upstream Analysis
• 12.3 Radioactive Diagnostic Drugs Midstream Analysis
• 12.4 Radioactive Diagnostic Drugs Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Radioactive Diagnostic Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Radioactive Diagnostic Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radioactive Diagnostic Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radioactive Diagnostic Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radioactive Diagnostic Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radioactive Diagnostic Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radioactive Diagnostic Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radioactive Diagnostic Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Curium, Medi-Radiopharma, Jubilant Radiopharma, Telix, Mallinckrodt, Cardinal Health, Bayer AG, GE Healthcare, Mallinckrodt Pharmaceuticals, Bracco Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radioactive Diagnostic Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Single Photon Drugs
Positron Drugs
Blood Perfusion Drugs
Metabolizing Drugs
Receptor Binding Drugs
Others
Market segment by Application
Oncology
Cardiology
Neuroscience
Thyroid
Others
Market segment by players, this report covers
Curium
Medi-Radiopharma
Jubilant Radiopharma
Telix
Mallinckrodt
Cardinal Health
Bayer AG
GE Healthcare
Mallinckrodt Pharmaceuticals
Bracco Group
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radioactive Diagnostic Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radioactive Diagnostic Drugs, with revenue, gross margin, and global market share of Radioactive Diagnostic Drugs from 2021 to 2026.
Chapter 3, the Radioactive Diagnostic Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Radioactive Diagnostic Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radioactive Diagnostic Drugs.
Chapter 13, to describe Radioactive Diagnostic Drugs research findings and conclusion.